{"name":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","slug":"sunshine-guojian-pharmaceutical-shanghai-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CPGJ602","genericName":"CPGJ602","slug":"cpgj602","indication":"Type 2 diabetes","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"609A","genericName":"609A","slug":"609a","indication":"Unknown indication","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"SSGJ-707","genericName":"SSGJ-707","slug":"ssgj-707","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]}],"pipeline":[{"name":"CPGJ602","genericName":"CPGJ602","slug":"cpgj602","phase":"phase_2","mechanism":"CPGJ602 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"609A","genericName":"609A","slug":"609a","phase":"phase_2","mechanism":"609A is a small molecule drug that targets the molecular target.","indications":["Unknown indication"],"catalyst":""},{"name":"SSGJ-707","genericName":"SSGJ-707","slug":"ssgj-707","phase":"phase_3","mechanism":"SSGJ-707 is a small molecule that targets the PD-1/PD-L1 pathway.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxOZHVjR056OWh1cUd2SHRCcFB6T3dVN2hDN2pzOTFadWlyaVViS1RIbkppU0xiZ0VtMlptOHUybVl6V0w2ZElNQVp4M3VlQjEwYWN1NTdGLWNId0FqTjhpTTlZck5ldHNncG02TVk4cVkwbTdlTWd4SEplU3AwNjBGT3ZoMHJPZnRlS2MtejVCU1VQYzNLUFBpN0c4alp4TTVod2hGbXZ1ZV9GdWVub3VpWnE4SndmTXdVaFRPeDYyOUtiRVdWOEZqNmpOX2JVNDRaLWFFSTVYQ3F4LVZQYkhLOVNIaC0?oc=5","date":"2026-03-12","type":"earnings","source":"Markets Mojo","summary":"Sunshine Guojian Pharmaceutical Reports Record Cash Flow and Strong Profit Growth - Markets Mojo","headline":"Sunshine Guojian Pharmaceutical Reports Record Cash Flow and Strong Profit Growth","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNNC1lbGZmZUw1QXpCOUotam52cDloS3RwbnhUWnBlN2JrTUVUMUw5enJEZjVLYmNaeEdid2tYQUgtSEZNSWZpc0Y4QVViSnY4WmNWZ0lKRC1kUzZiRUdGSXJyc3BWTEo1UzRyZERSOXF5YmVNOW81aWZHc1ZxaGd0Sw?oc=5","date":"2026-01-04","type":"patent","source":"Insightace Analytic","summary":"Psoriasis Biosimilars Market Size, Share and New Trends 2026 to 2035 - Insightace Analytic","headline":"Psoriasis Biosimilars Market Size, Share and New Trends 2026 to 2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQYjNrb1ZmNkxHdmlkS1RNZjJ6Q0VtT1d1d1ZMUXN6alNnOUVjM0s1bHFWWURZSFJHckxjWXJ0eU85UG9YVHBXTVBFUkFCQjFHSUFTam5VRWxwLVp2WFlJRzFmdTFnSFZJU0NTbk5idmttXy1faVJRU3lVOUNqWGVXWTJ3?oc=5","date":"2025-06-25","type":"patent","source":"Insightace Analytic","summary":"TNF Biosimilars Market is expected to grow at a 16.5% CAGR during the forecast period for 2025-2034. - Insightace Analytic","headline":"TNF Biosimilars Market is expected to grow at a 16.5% CAGR during the forecast period for 2025-2034.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPY3Iyb1lONTV2QVVTSTAyNFMyaW1BeU03VWVLaFlzYmhVemwzY0I5WTZzVHBFNFNsbzZsVmdFSHlnMTdpLWRxMlNReXlCelZVaENLRGRwUUFwc1dEdldHZzliSk11SWx0bzVWQ1drSFF0NDhiUjd1OHdkS0hpM3ZTT2FaZ1hkM2ZLbU1ocmNhRFNHbTBwRTlnMHVCTzIwbk9kVGxibXRSMFFaSlUy?oc=5","date":"2025-06-11","type":"trial","source":"BioWorld News","summary":"3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race - BioWorld News","headline":"3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPMkgwN1ZRX1FhUjNFS3pEUm9zNXY1WHV6TjdrOGU2NjcxdEdCSFBzSl96ZFNpaFJpX3UtU0hqaVFCWTlxWEk0TVhDRk1jNV94VnNRbWc4UUk4SnVPaUpTM0hjb3BEUGIwbW1FM21qLXdFUWkyTGJrM3RidEhGZDZseG9CU1dha1YyWU9R?oc=5","date":"2025-05-29","type":"deal","source":"thebambooworks.com","summary":"3SBio hits the big time with $6 billion cancer drug deal - thebambooworks.com","headline":"3SBio hits the big time with $6 billion cancer drug deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOTkd4M1hlSHFSc3FaTk40MzhjTWZqaS1YZnFxNmRsdHRiVndUM2tVN0w3OGVpZ3daaHBBLV9RMnJGdll5OXBBNXB6WUxHbWp4eTJiUERJTHJhZTlBWUJlUjI4Qk5wTm5mam1uX0JYOUxVX2Q0UU5Jek9vNE9wTDNFcGN6TWRlSkt4d21scUI1RUd2WkNuR3JEUmp5TQ?oc=5","date":"2025-05-20","type":"pipeline","source":"BioWorld News","summary":"Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody - BioWorld News","headline":"Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxQUlBEN2JQMkVlejVsUDE0d0pQcXhDTHBHdE1nMmhzTVNERFBfTDkzWW83Yi1ZZEpBbHowUjA1S0VpNnJ2NXZnUHRJY09NUDVxZnp2WFNxc1I2Q0x3dTFldXhFNm5JUDR5MlA4a0tDeTUxYm5WYTZMVzZUczJHYjBHbDFFaDRiTDZTSlJNRzFnbHBjNUYwNkR3ejJGa3AweDlpeVdhdk5ucGJmSHctSTdHS3g5N2lMYU1fMDB3TlYtUlBScG4zYUI4bk5LQjVlaGt3blZ5OWRfdkVCY2NFcWYtZ1UxVGxrZWJtZExQSGxFYUN4c1ZSQWhaZkxhT1M1RXRudlNuRXNlMXQ3MzFPMkZTeFRvS3VVaHprWlpsazd1akZOUQ?oc=5","date":"2024-11-06","type":"trial","source":"PR Newswire","summary":"Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire","headline":"Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxNTmtpYURaVEhPYkNqc0FkczdWaHNyQXpkVXRSaVRUT0RDTm42bDQ1N1d3eDh6ZXd6czdkVGdPak5IbGxaekROMEduQnJ2LUdzMFJpbTNyVlRuVDBQMmxHbFZFTlBOS3JvbkgwMVYxSEJnenNnU0dvaF9yUDMtTmxjcXVMeWRxX1hMZ3hTcXdVdFpGM0tUYjFmdHIxbDh4OE5iTVlBQ3Q4V2JyY0g1cWpnZmdzV21yMktObTJNMmY3X2FBQ2R0aXBKbEtOOElkdS1iSnd3SGNRWHNlYzdVT3VBTkh4cklVU0dsaWF2dlhmUnZKNmRBLUplLVhpSm8tODJnNVdHVWlxQUR3U1ZIRVFxYVdPczVMSXhxOGc?oc=5","date":"2023-05-10","type":"pipeline","source":"PR Newswire","summary":"Soft Tissue Sarcoma Pipeline Space Brims With Novel Emerging Therapies with Over 125 Key Companies Working in the Domain | DelveInsight - PR Newswire","headline":"Soft Tissue Sarcoma Pipeline Space Brims With Novel Emerging Therapies with Over 125 Key Companies Working in the Domain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQQkt4U3ctMDhDVDlNeXFwNjY0UDE3a0dWc0JVX05GWURnS1F0bFBKVTZ6QnJhY1hOdkdURHgwLTVKMjR1cXRULUtkVnBmVUFuUnZTRlZFdnV2SDVnaDIwOXk5TkVHM3Z0MTFHXzhBNnZPZ1dWZHhjMmhqdlFGTWM4YWUyNGRURkF4MkJyWHpuZVcwMzlLWWRMbVk0cVQzLXVTYk81NUxGLWs?oc=5","date":"2022-01-06","type":"deal","source":"BioWorld News","summary":"3Sbio licenses out global rights of PD-1 inhibitor to Syncromune - BioWorld News","headline":"3Sbio licenses out global rights of PD-1 inhibitor to Syncromune","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":2,"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}